Please login to the form below

Not currently logged in
Email:
Password:

Bayer gets US green light for colorectal cancer drug Stivarga

Follows FDA approval for Sanofi and Regeneron's Zaltrap in same indication

Bayer research centre Berlin

The US Food and Drug Administration (FDA) has approved Bayer's new colorectal cancer drug Stivarga following a review period of just five months on the back of data showing it can improve survival.

Stivarga (regorafenib) - a multi-kinase inhibitor that blocks several enzymes that promote cancer growth - has been given a green light as a second-line treatment for patients with metastatic colorectal cancer, just weeks after the FDA cleared Sanofi and Regeneron's Zaltrap (ziv-aflibercept) for the same indication.

Bayer's drug improved overall survival in these patients by an impressive 29 per cent in the phase III CORRECT trial, leading some observers to suggest that the drug could become a new standard of care. It also had a significant impact on progression-free survival (PFS) and disease control rates.

"The approval of regorafenib adds to the treatments we have for metastatic colorectal cancer, which is important for those patients who have no further options," said CORRECT investigator Heinz-Josef Lenz of the USC Norris Comprehensive Cancer Center.

"The drug has been shown to prolong survival and slow the progression of cancer in patients whose disease had progressed after treatment with currently available therapies. It provides patients another avenue to fight this cancer," he added.

CORRECT showed that even in a hard-to-treat population which had been exposed to earlier chemotherapy regimens, regorafenib was able to boost overall survival to 6.4 months versus 4.0 months with placebo.

Similarly, PFS was increased to 2.0 months from 1.7 months with placebo, while the disease control rate was nearly 45 per cent in those treated with Bayer's drug and just 15 per cent for the control group.

Regorafenib is one of four late-stage compounds that Bayer has predicted could collectively add €5bn to its revenues at peak. The company filed regorafenib as a treatment for gastrointestinal stromal tumours (GIST) in the US in August and the drug has also been filed for colorectal cancer in Europe.

The compound caused a dispute between Bayer and partner Onyx Pharmaceuticals, which filed a lawsuit in 2009 claiming rights to the drug under the terms of an alliance between the two firms which led to the development of kidney and liver cancer drug Nexavar (sorafenib).

The suit was settled last year after the two companies agreed that regorafenib is a Bayer compound but Onyx would receive a 20 per cent royalty on sales.

1st October 2012

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...